Holoclara is pioneering the first therapeutic class designed to selectively modulate intracellular receptor trafficking - a fundamental membrane-linked process that shapes immune activity.

HC-002, our lead candidate, has completed Phase 1 with strong safety, tolerability, and linear PK. Phase 1 data demonstrates this axis is safe and tractable, and ongoing work is clarifying its translational relevance and class potential. HC-002 target data to show with CDA.

Holoclara aims to partner with groups seeking first-line or biologic-complementary oral therapies to broaden access and address major unmet needs across inflammatory disease.